Literature DB >> 31076442

The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.

Shi Hao Tan1, Wei Zhong Leong1, Phuong Cao Thi Ngoc1, Tze King Tan1, Fatima Carla Bertulfo1, Mei Chee Lim1,2, Omer An1, Zhenhua Li3, Allen Eng Juh Yeoh3, Melissa J Fullwood1,4, Daniel G Tenen1,5,6, Takaomi Sanda1,6.   

Abstract

The oncogenic transcription factor TAL1 regulates the transcriptional program in T-ALL. ARID5B is one of the critical downstream targets of TAL1, which further activates the oncogenic regulatory circuit in T-ALL cells. Here, we elucidated the molecular functions of the noncoding RNA, ARID5B-inducing enhancer associated long noncoding RNA (ARIEL), in T-ALL pathogenesis. We demonstrated that ARIEL is specifically activated in TAL1 + T-ALL cases, and its expression is associated with ARID5B enhancer activity. ARIEL recruits mediator proteins to the ARID5B enhancer, promotes enhancer-promoter interactions, and activates the expression of ARID5B, thereby positively regulating the TAL1-induced transcriptional program and the MYC oncogene. The TAL1 complex coordinately regulates the expression of ARIEL Knockdown of ARIEL inhibits cell growth and survival of T-ALL cells in culture and blocks disease progression in a murine xenograft model. Our results indicate that ARIEL plays an oncogenic role as an enhancer RNA in T-ALL.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31076442     DOI: 10.1182/blood.2018874503

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Finding ARIEL under the sea of T-ALL circuits.

Authors:  Mark Y Chiang
Journal:  Blood       Date:  2019-07-18       Impact factor: 22.113

2.  Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines.

Authors:  Hiroki Hosoi; Akiko Niibori-Nambu; Giselle Sek Suan Nah; Avinash Govind Bahirvani; Michelle Meng Huang Mok; Takaomi Sanda; Alan Prem Kumar; Daniel G Tenen; Yoshiaki Ito; Takashi Sonoki; Motomi Osato
Journal:  Gene       Date:  2021-01-12       Impact factor: 3.688

3.  Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential.

Authors:  Joo-Hyung Lee; Feng Xiong; Wenbo Li
Journal:  RNA Biol       Date:  2020-01-19       Impact factor: 4.652

Review 4.  Long noncoding RNAs: emerging regulators of normal and malignant hematopoiesis.

Authors:  Yi Qiu; Mingjiang Xu; Suming Huang
Journal:  Blood       Date:  2021-12-09       Impact factor: 22.113

Review 5.  Enhancer RNAs are an important regulatory layer of the epigenome.

Authors:  Vittorio Sartorelli; Shannon M Lauberth
Journal:  Nat Struct Mol Biol       Date:  2020-06-08       Impact factor: 15.369

Review 6.  The essential but enigmatic regulatory role of HERVH in pluripotency.

Authors:  Corinne E Sexton; Richard L Tillett; Mira V Han
Journal:  Trends Genet       Date:  2021-07-30       Impact factor: 11.639

Review 7.  Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia.

Authors:  Laura Belver; Robert Albero; Adolfo A Ferrando
Journal:  Trends Immunol       Date:  2021-04-12       Impact factor: 16.687

Review 8.  lncRNAs in T lymphocytes: RNA regulation at the heart of the immune response.

Authors:  Leah M Plasek; Saba Valadkhan
Journal:  Am J Physiol Cell Physiol       Date:  2020-12-09       Impact factor: 4.249

9.  Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Zhang Chen; Fan Yang; Hui Liu; Fan Fan; Yanggang Lin; Jinhua Zhou; Yun Cai; Xiaoxiao Zhang; Yingxin Wu; Rui Mao; Tongtong Zhang
Journal:  Aging (Albany NY)       Date:  2021-06-09       Impact factor: 5.682

10.  TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.

Authors:  Lin Cheng; Tong Han; Bolin Chen; Kechao Nie; Weijun Peng
Journal:  BMC Cancer       Date:  2021-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.